SCHEMBL25868173

SCHEMBL25868173

CC(C)CNC(=O)CCNC(=O)CCNC(=O)CCC(=O)C(C)C

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 5/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C19 P33261 2/20 0.42
HPGD P15428 5/20 0.41
ALDH1A1 P00352 2/20 0.41
EPHX1 P07099 1/20 0.40
MAPT P10636 1/20 0.38
MMP1 P03956 1/20 0.37
MMP8 P22894 1/20 0.37
GAA P10253 1/20 0.36
RECQL P46063 2/20 0.36
NAMPT P43490 1/20 0.35
USP2 O75604 1/20 0.35
KAT2A Q92830 1/20 0.35
KAT2B Q92831 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13669328 0.92 CYP2D6 (0.48) EPHX2CYP2D6CYP2C19HPGDALDH1A1
SCHEMBL25029528 0.89 HPGD (0.46) EPHX2CYP2D6CYP2C19HPGDALDH1A1
SCHEMBL25084228 0.84 ALDH1A1 (0.44) EPHX2CYP2D6CYP2C19HPGDALDH1A1
SCHEMBL16248549 0.81 LMNA (0.49) CYP2C19HPGDALDH1A1MAPTGAA
SCHEMBL18084529 0.81 HPGD (0.51) EPHX2CYP2D6CYP2C19HPGDEPHX1
SCHEMBL13853865 0.81 EPHX1 (0.46) EPHX2CYP2D6CYP2C19HPGDALDH1A1
SCHEMBL16724729 0.79 HPGD (0.46) EPHX2CYP2D6CYP2C19HPGDALDH1A1
SCHEMBL23729626 0.79 HPGD (0.50) EPHX2CYP2D6CYP2C19HPGDEPHX1
SCHEMBL23729571 0.79 HPGD (0.50) EPHX2CYP2D6CYP2C19HPGDEPHX1
SCHEMBL23729625 0.79 HPGD (0.50) EPHX2CYP2D6CYP2C19HPGDEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins UNIV YALE (US) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A EPHX2 1875/4885CYP2D6 4501/4885CYP2C19 4615/4885
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins ASGR1, LDLR, FCGR2A EPHX2 2895/4885CYP2D6 2423/4885CYP2C19 2385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.